| 1.7301 -0.2 (-10.36%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.42 |
1-year : | 3.15 |
| Resists | First : | 2.07 |
Second : | 2.7 |
| Pivot price | 2.12 |
|||
| Supports | First : | 1.07 |
Second : | 0.89 |
| MAs | MA(5) : | 1.94 |
MA(20) : | 2.15 |
| MA(100) : | 2.24 |
MA(250) : | 3.69 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.6 |
D(3) : | 15.5 |
| RSI | RSI(14): 34.3 |
|||
| 52-week | High : | 8.97 | Low : | 1.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BGLC ] has closed above bottom band by 9.4%. Bollinger Bands are 65.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.92 - 1.93 | 1.93 - 1.94 |
| Low: | 1.71 - 1.72 | 1.72 - 1.73 |
| Close: | 1.72 - 1.73 | 1.73 - 1.74 |
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Sat, 27 Jun 2026
Price to book forward of BioNexus Gene Lab Corp – NASDAQ:BGLC - TradingView
Wed, 17 Jun 2026
BioNexus Gene Lab Corp (BGLC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Thu, 11 Jun 2026
12 Industrials Stocks Moving In Thursday's Pre-Market Session - Benzinga
Fri, 29 May 2026
BioNexus Gene Lab Corp (BGLC) Slips 3.33% as Stock Tests Key Support at $2.20 - Long Term Entry Picks - dars.gov.et
Fri, 29 May 2026
BioNexus Gene Lab Corp (BGLC) Slips 3.33% as Stock Tests Key Support at $2.20 - Fibonacci Arc - dars.gov.et
Fri, 29 May 2026
BioNexus Gene Lab Corp (BGLC) Declines 8.33% as Stock Approaches Key Support - OBV Divergence - dars.gov.et
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Industrials
|
|
|
Industry:
Industrial - Distribution
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.76e+006 (%) |
| Held by Institutions | 35.5 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.96e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -54.8 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 466 % |
| Return on Equity (ttm) | -20.8 % |
| Qtrly Rev. Growth | 5.31e+006 % |
| Gross Profit (p.s.) | -45.16 |
| Sales Per Share | -16.73 |
| EBITDA (p.s.) | 338324 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 1.13 |
| Dividend | 0 |
| Forward Dividend | 99210 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|